lisdexamfetamine / Generic mfg. - LARVOL DELTA

Insomnia is associated with psychological distress in individuals with methamphetamine dependence. (PubMed, Australas Psychiatry) - "This study examined the relationship between insomnia severity and psychological distress in treatment-seeking individuals with methamphetamine dependence.MethodsThis is a secondary cross-sectional analysis of baseline data from 152 participants enrolled in a randomised controlled trial of lisdexamfetamine versus placebo for methamphetamine dependence. In adjusted models, insomnia remained associated with distress: each 1-point ISI increase related to a 2.1-2.5% rise in DASS-21 depression and stress scores (β = 0.021-0.025, p = .003-.007), and a 6.5% increase in total scores (β = 0.063, p < .001); the association with anxiety was attenuated.ConclusionsOur study identified insomnia as an independent correlate of psychological distress in treatment-seeking individuals with methamphetamine dependence. Findings underscore sleep problems' relevance and support further research into sleep-focused interventions."

Journal • CNS Disorders • Depression • Insomnia • Mood Disorders • Psychiatry • Sleep Disorder

Pharmacological management of binge eating disorder. (PubMed, Ment Health Clin) - "Treatment guidelines for binge eating disorder (BED) lack substantial recommendations for specific pharmacological management beyond lisdexamfetamine. This may lead clinicians to question what other options are available for managing BED. The following clinical scenarios will review existing data examining the use of several pharmacological agents for BED, including stimulants, glucagon-like peptide-1 agonists, naltrexone, antidepressants, and antiseizure medications."

Journal • Binge Eating Disorder • CNS Disorders • Epilepsy

Vyvanse in Children Aged 6 to 12 Years (clinicaltrials.gov) - P1 | N=40 | Recruiting | Sponsor: University of Minnesota | Trial completion date: Nov 2029 ➔ Jul 2027 | Trial primary completion date: Nov 2028 ➔ Jul 2026

Trial completion date • Trial primary completion date • Genetic Disorders • Obesity

Approved and Pipeline Pharmacological Interventions for Eating Disorders (2010-2025): 15 Years of Progress (or Lack Thereof). (PubMed, CNS Drugs) - "Among 24 distinct compounds studied, only 1 agent, lisdexamfetamine dimesylate, received approval from the U.S. Food and Drug Administration (FDA) for an ED during this period...While some emerging agents show promise, such as solriamfetol and psilocybin, there remains a significant lack of evidence-based pharmacological interventions for anorexia nervosa and a dearth of progress in pharmacotherapy for bulimia nervosa. Overall, the past 15 years have witnessed limited advancements in pharmacotherapy for EDs. There remains an urgent need for rigorous clinical trials in this area in addition to increased prioritization of ED research at the public health level to overcome longstanding barriers in the treatment of EDs."

Journal • Review • Anorexia • Binge Eating Disorder • Bulimia • CNS Disorders • Psychiatry

Study protocol for a randomised controlled trial to determine the efficacy of lisdexamfetamine for the treatment of acute methamphetamine withdrawal in inpatient settings. (PubMed, BMJ Open) - P4 | "Findings will be presented such that individual participants will not be identifiable. ACTRN12624001061527."

Clinical protocol • Journal • CNS Disorders • Depression • Insomnia • Mood Disorders • Psychiatry • Sleep Disorder

Differential effects of a single dose of Lisdexamfetamine and Guanfacine on cognitive function in children with ADHD. (PubMed, Front Psychiatry) - P=N/A | "Findings suggest that guanfacine, unlike lisdexamfetamine, may not improve attention in children and adolescents with ADHD. https://clinicaltrials.gov/study/NCT03333668?term=NCT03333668&rank=1#study-plan, identifier NCT03333668."

Journal • ADHD (Impulsive Aggression) • Alzheimer's Disease • Attention Deficit Hyperactivity Disorder • CNS Disorders • Cognitive Disorders • Psychiatry

Lisdexamfetamine-Induced Angioedema and Leukocytoclastic Vasculitis: A Case Report. (PubMed, Australas J Dermatol) - "A positive rechallenge after an extensive workup confirmed a drug-induced reaction. This case highlights lisdexamfetamine as a cause of non-allergic angioedema and leukocytoclastic vasculitis, and demonstrates the diagnostic value of a medication history and rechallenge."

Journal • ADHD (Impulsive Aggression) • Alpha-1 Antitrypsin Deficiency • Attention Deficit Hyperactivity Disorder • Cardiovascular • CNS Disorders • Immunology • Psychiatry • Pulmonary Disease • Respiratory Diseases • Vasculitis

Raynaud's phenomenon during treatment with lisdexamfetamine: risk of cerebral vasospasm? (PubMed, Einstein (Sao Paulo)) - "Lisdexamfetamine, a prodrug used to treat Attention Deficit/Hyperactivity Disorder in children, adolescents, and adults, is an inactive substance that is converted into its active form (dextroamphetamine) after being metabolized. In both patients presented in this report, discontinuation of the medication led to resolution of the phenomenon within a few days. This report highlights the fact that one of the patients reported episodes of dizziness during Raynaud's phenomenon, drawing attention to the potential associated complications."

Journal • ADHD (Impulsive Aggression) • Attention Deficit Hyperactivity Disorder • Cardiovascular • CNS Disorders • Psychiatry • Rheumatology

Involvement of the histaminergic system on maladaptive feeding behavior in an animal model of binge eating in female rats (Neuroscience 2025) - "To date, lisdexamfetamine dimesylate remains the only FDA-approved pharmacotherapy for BED, highlighting the urgent need for novel therapeutic approaches...Notably, pharmacological enhancement of HA transmission, both acutely and chronically, effectively suppressed binge-like behavior and prevented several of the associated molecular alterations. These findings suggest a potential involvement of the HA system in the pathophysiology of binge eating and support its consideration as a novel pharmacological target for BED treatment."

Preclinical • Binge Eating Disorder • CNS Disorders

Exposures to attention deficient hyperactivity disorder medications reported to the New South Wales Poisons Information Centre (2014-2023): A retrospective study. (PubMed, Aust N Z J Psychiatry) - "Exposures to attention deficit hyperactivity disorder medications present a growing public health issue. Rates have risen annually over the past decade, and the majority require medical attention, placing strain on healthcare resources. There are notable differences in exposure patterns among affected age groups. This highlights the need for targeted preventive measures focused on both quality use of the medication being prescribed as well as considering the circumstances and safety of the individual and household."

Journal • Retrospective data • ADHD (Impulsive Aggression) • Attention Deficit Hyperactivity Disorder • CNS Disorders • Psychiatry

Disparities in Obesity Medication Dispensing Among Adolescents in Real-World Settings (OBESITY WEEK 2025) - "We included commonly prescribed OMs in our healthcare system, including Semaglutide, Liraglutide, Tirzepatide, Phentermine, Topiramate, Phentermine-Topiramate, Metformin, and Lisdexamfetamine... This is the first study to examine the likelihood of OM dispensing in a pediatric population. We identified stark disparities in whether an OM was dispensed by insurance, sex, and obesity severity—particularly for newer GLP-1 receptor agonists. As OM use continues to rise among youth, these gaps may widen without intentional intervention."

Clinical • Real-world • Real-world evidence • Diabetes • Genetic Disorders • Metabolic Disorders • Obesity • Pediatrics

Attention-deficit hyperactivity disorder medication use in pregnancy and risk of miscarriage. (PubMed, Br J Psychiatry) - "ADHD medication use during pregnancy is associated with increased miscarriage risk. However, filled prescriptions may not reflect actual use. Further research is needed to clarify these associations and refine risk estimates."

Journal • ADHD (Impulsive Aggression) • Attention Deficit Hyperactivity Disorder • CNS Disorders • Psychiatry

A randomised controlled trial to evaluate the clinical and cost-effectiveness of Stimulant compared with Non-stimulant medication for adults with Attention-deficit/hyperactivity disorder and a history of Psychosis or biPolar disordER: SNAPPER. (PubMed, Trials) - "Given that untreated ADHD is associated with poor clinical outcomes, unemployment and criminal justice system involvement, clear evidence in this area is likely to improve recovery for individuals with ADHD and a history of SMI, reducing costs for the individual, the NHS and society."

HEOR • Journal • ADHD (Impulsive Aggression) • Attention Deficit Hyperactivity Disorder • Bipolar Disorder • CNS Disorders • Developmental Disorders • Mood Disorders • Psychiatry

Prescription Stimulants Can Increase Risk of Arrhythmias: Systematic Review and Meta-Analysis (AHA 2025) - "These agents, including amphetamines, methylphenidate, modafinil, and lisdexamfetamine, elevate sympathetic tone and may precipitate cardiac arrhythmias, including atrial fibrillation (AF) and ventricular tachyarrhythmias. All major stimulant subclasses were significantly associated with increased arrhythmia risk, with the highest risk observed in amphetamines. These findings emphasize the potential cardiovascular consequences of stimulant therapy and reinforce the need for ongoing cardiac monitoring. Further research is warranted to delineate the safety profiles of individual stimulant medications."

Retrospective data • Review • ADHD (Impulsive Aggression) • Atrial Fibrillation • Attention Deficit Hyperactivity Disorder • Cardiovascular • CNS Disorders • Narcolepsy • Psychiatry • Sleep Disorder • Ventricular Tachycardia

Stimulant-Induced Ischemic Colitis (ACG 2025) - "Of note, she had transitioned from lisdexamfetamine (Vyvanse) to amphetamine-dextroamphetamine (Adderall) one month prior for management of ADHD. Figure: Coronal image from a CT of the abdomen and pelvis with IV contrast that demonstrates circumferential wall thickening of the colon at the splenic flexure with associated mild peri-colonic fat stranding. Not captured on this single slice image is that these findings involve a longer segment of the colon including an entirety of the splenic flexure."

ADHD (Impulsive Aggression) • Atherosclerosis • Attention Deficit Hyperactivity Disorder • Cardiovascular • CNS Disorders • Dermatology • Gastroenterology • Gastrointestinal Disorder • Hematological Disorders • Immunology • Psychiatry • CRP

Local Data, National Crisis: Pediatric ADHD Treatment Disruptions Amid 2024 Stimulant Shortages (AACAP 2025) - "All data used were deidentified. Of 51 total encounters, the most commonly affected medication was Vyvanse (n = 20, 39.2%), followed by Concerta (n = 14, 27.5%), Focalin XR (n = 10, 19.6%), Ritalin (n = 4, 7.8%), and Adderall (n = 3, 5.9%). These findings provide a real-time clinical snapshot of how stimulant shortages disrupted ADHD care among vulnerable pediatric populations. Even when prescriptions were ultimately filled, the process introduced delays, suboptimal substitutions, and increased burdens on families and providers. These disruptions risk exacerbating symptoms such as impulsivity, inattention, and emotional dysregulation in youth."

Clinical • ADHD (Impulsive Aggression) • Attention Deficit Hyperactivity Disorder • CNS Disorders • Pediatrics • Psychiatry

Pharmacological management of attention deficit hyperactivity disorder in children and adolescents. (PubMed, Aust Prescr) - "Stimulants (methylphenidate, dexamfetamine, lisdexamfetamine) are the main pharmacological treatment for children and adolescents with ADHD and are highly effective at reducing core ADHD symptoms. Non-stimulants such as atomoxetine, clonidine and guanfacine can also be useful in some patients."

Journal • Review • ADHD (Impulsive Aggression) • Attention Deficit Hyperactivity Disorder • CNS Disorders • Developmental Disorders • Psychiatry

Global Trends in ADHD Medication Use: Multiple Contexts and Rising Concerns-A Narrative Review. (PubMed, J Clin Med) - "Methylphenidate remained the most widely prescribed drug, although the use of lisdexamfetamine and guanfacine has expanded in recent years...Increasing use of ADHD medications raises important questions about equitable access to treatment, potential overdiagnosis, and the risk of stimulant misuse. These findings highlight the need for continued monitoring of utilization patterns to ensure safe, rational, and equitable ADHD care worldwide."

Journal • Review • ADHD (Impulsive Aggression) • Attention Deficit Hyperactivity Disorder • CNS Disorders • Psychiatry

Recent developments in treatments for eating disorders. (PubMed, Neurotherapeutics) - "Only two medications have received FDA approval for the treatment of eating disorders - fluoxetine for BN and lisdexamfetamine for BED. Existing treatments are not universally effective, and relapse rates are still elevated among those who do respond to treatment. Psychotherapies such as the habit-interrupting REACH ​+ ​for AN and biological treatments including neuromodulation techniques that target specific brain regions implicated in the development and maintenance of eating disorders warrant further study."

Journal • Review • Anorexia • Binge Eating Disorder • Bulimia • CNS Disorders • Mental Retardation • Psychiatry

Clinical study on the treatment of leukopenia after chemotherapy with leucogen tablets and Shengbai mixture. (PubMed, Pak J Pharm Sci) - "The intervention group (48 patients) received lisdexamfetamine (20 mg, TID) plus leucovorin (20 mL, TID), while the control group (48 patients) received lisdexamfetamine only. No significant difference in adverse events was observed between groups (10.42% vs 18.75%; P=0.247). The combination of Shengbai mixture and leucogen demonstrates significantly enhanced myeloprotective efficacy with safety profiles comparable to those of leucogen monotherapy, thereby underscoring its potential as a highly effective therapeutic modality."

Clinical • Journal • Hematological Disorders • Leukopenia

AMPHETAMINE-INDUCED ACUTE EOSINOPHILIC PNEUMONIA AND ASSOCIATED PNEUMOMEDIASTINUM (CHEST 2025) - "In the outpatient setting, she completed prednisone taper alongside Pneumocystis pneumonia prophylaxis. Ultimately, our patient fits the diagnostic criteria of AEP, believed to be secondary to lisdexamfetamine, which adds a new offender to the list of medications associated with AEP. Bartal et al. (2018) have previously described a total 196 case reports identifying 67 different medications having caused AEP [3]."

ADHD (Impulsive Aggression) • Asthma • Attention Deficit Hyperactivity Disorder • CNS Disorders • Cough • Diabetes • Endocrine Disorders • Eosinophilia • Immunology • Infectious Disease • Interstitial Lung Disease • Metabolic Disorders • Pertussis • Pneumonia • Psychiatry • Respiratory Diseases • Type 2 Diabetes Mellitus

Glucagon-like peptide-1 receptor agonists: new binge eating treatment? (ECNP 2025) - "Meanwhile, topiramate and lisdexamfetamine (LDX) have demonstrated efficacy in both reducing BE episodes and promoting weight loss, but their clinical application is restricted by notable adverse effects... A literature search was conducted across PubMed, Scopus and Web of Science databases, using different combinations of the terms "GLP-1 receptor agonist", "binge eating", "eating disorder", "binge eating disorder", "bulimia nervosa", "liraglutide", "semaglutide"... GLP-1RAs represent a potentially effective pharmacological approach to managing binge eating and associated metabolic dysregulation, but their integration into EDs treatment requires caution due to potential interference with core therapeutic strategies. Further rigorous studies are warranted to establish their safety, efficacy, and appropriate clinical use in eating disorder populations."

Anorexia • Binge Eating Disorder • Bulimia • CNS Disorders • Depression • Mood Disorders • Psychiatry

Naltrexone-bupropion: a new solution for binge eating disorder (ECNP 2025) - "With limited evidence available on pharmacotherapy for BED, since lisdexamfetamine is only approved in some countries, new drugs are needed...Others confirmed the effectiveness of weight reduction in patients with BED, but failed to prove the reduction in binge eating episodes. Further research is needed to deeply explore these findings, balancing their benefits but also their risks, promoting responsible prescribing practices."

Anorexia • Binge Eating Disorder • Bulimia • CNS Disorders

From spectrum to symptoms: rethinking eating disorders through a neurodevelopmental lens (ECNP 2025) - "Moreover, pharmacological treatments such as lisdexamfetamine have shown efficacy in treating BED, particularly in individuals with comorbid ADHD, by targeting underlying impulsivity and executive function deficits [5]...Importantly, future studies should explore gender differences, as females with NDCs often remain underdiagnosed, particularly in the context of restrictive EDs. A deeper understanding of these intersections could foster more equitable, effective, and personalized mental health care."

Neurodevelopmental • ADHD (Impulsive Aggression) • Anorexia • Attention Deficit Hyperactivity Disorder • Binge Eating Disorder • CNS Disorders • Psychiatry

S21 – Binge-eating disorder: from mechanism to novel treatments (ECNP 2025) - "Pharmacological approaches, such as lisdexamfetamine dimesylate, have shown efficacy in reducing both weight and binge-eating episodes, but associated side effects underscore the need for alternative therapies...> The Symposium is 80 minutes: each of the 4 speakers has 15 minutes to present, followed by 5 minutes of Questions and Answers. > The audience is invited to submit questions by using the ECNP 2025 app or by scanning the QR code in the session room, verbal questions will not be taken."

Binge Eating Disorder • CNS Disorders • Mood Disorders • Psychiatry • Substance Abuse